{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-263724","form_type":"8-K","ticker":"LBRX","cik":"0001691082","company_name":"LB PHARMACEUTICALS INC","filed_at":"2026-06-09T20:05:22+00:00","discovered_at":"2026-06-09T20:06:01.332386+00:00","generated_at":"2026-06-09T20:06:09.102255+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"LB Pharma shareholders elect three Class I directors, ratify auditor at annual meeting","bullets":["Class I directors elected: Robert A. Lenz (20,059,577 for), Rebecca Luse (18,530,680), Ran Nussbaum (18,748,511).","Broker non-votes of 3,216,636 on each director election.","Ratification of BDO USA as auditor for FY 2026: 23,275,974 for, 5,490 against, 2,753 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-263724","json":"https://secwatch.observer/filing/0001193125-26-263724.json","markdown":"https://secwatch.observer/filing/0001193125-26-263724.md","text":"https://secwatch.observer/filing/0001193125-26-263724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526263724/0001193125-26-263724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526263724/d138757d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T20:06:09.102255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b029068599075bb1952c82a0a28ead692dd13a3","claim":"LB PHARMACEUTICALS INC shareholders approved Ratification of the appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526263724/0001193125-26-263724-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"},{"claim_id":"9048fd976b6d48487614452e34eae4c4e30cb006","claim":"LB PHARMACEUTICALS INC shareholders approved Election of Class I Directors to serve three-year terms until 2029 at the 2026-06-03 meeting.","evidence_excerpt":"The Company’s stockholders elected the three persons listed below as Class I directors, each to serve a three-year term until the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526263724/0001193125-26-263724-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}